TRIUMPH: 58% of acute severe UC patients responded 'within 2 days' of starting Xeljanz

WASHINGTON — Nearly 60% of patients with acute severe ulcerative colitis responded to Xeljanz 10 mg twice daily by day 7, with one-third of patients in steroid-free remission by 6 months, according to interim analysis data presented here.
“There are few recommended therapies for acute severe UC management given the need for rapidly acting therapies,” Neeraj Narula, MD, MPH,

Related Keywords

Washington ,United States ,Heather Biele ,Neeraj Narula ,Byrobert Stott ,Mcmaster University ,Pfizer ,Clinic At Hamilton Health Sciences ,Triumph ,Hamilton Health Sciences ,Modified Truelove ,Witts Severity Index ,